Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis.
OBJECTIVE
To describe the medical treatment of severe ocular hypotony in HIV-seropositive patients with cytomegalovirus retinitis and cidofovir-associated uveitis.


METHODS
Two HIV-seropositive patients with cytomegalovirus retinitis and cidofovir-associated uveitis complicated by severe ocular hypotony were unresponsive to conventional therapy after treatment with cidofovir was stopped. They were subsequently treated successfully with ibopamine 2% eyedrops and dexamethasone 0.1% eyedrops.


RESULTS
In both cases, an increase in intraocular pressure to normal values was observed on average 18.5 days after starting treatment. Intraocular pressure remained stable while on therapy for a mean follow-up of 9.5 months. During the follow-up period, any attempt to stop treatment was followed by an intraocular pressure decrease; conversely, restoration of therapy increased intraocular pressure to normal values. No reactivation of cidofovir-associated uveitis or cytomegalovirus retinitis was observed during the follow-up period.


CONCLUSIONS
Ibopamine 2% eyedrops in combination with dexamethasone 0.1% eyedrops is a satisfactory therapy for severe ocular hypotony in patients with cytomegalovirus retinitis and cidofovir-associated uveitis.
Accorinti
M
M
Servizio Speciale di Immunovirologia Oculare, Istituto di Oftalmologia, Università di Roma La Sapienza, Rome, Italy.
Ciapparoni
V
V
Pirraglia
M P
MP
Pivetti-Pezzi
P
P
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077404:Cidofovir; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D003596:Cytosine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D015814:Ocular Hypotension / Q000139:chemically induced / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D014606:Uveitis, Anterior / Q000139:chemically induced*
D000998:Antiviral Agents; D018491:Dopamine Agonists; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003907:Dexamethasone; D003596:Cytosine; C023487:ibopamine; D000077404:Cidofovir; D003846:Deoxyepinephrine